We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

High-Dose Chemo Before RT Results in High Survival in Pediatric Brain Tumors

  • Leah Lawrence
Jun 10, 2014
  • ASCO 2014 Brain Tumors, Brain Tumors, ASCO, Pediatric Cancers

High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor (sPNET).

Christelle Dufour, MD, of Gustave Roussy, France, presented the results of the phase II study (abstract 10007) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

“The strategy based on intensified chemotherapy before craniospinal radiation provides high survival rates in children and adolescents with newly diagnosed high-risk cerebral PNET,” Dufour said during her presentation. “Analyses of neurocognitive and endocrinologic outcomes of these patients are ongoing.”

Medulloblastoma is the most common brain tumor in children. Patients with high-risk disease are those with residual postoperative disease or metastatic disease. More recently, patients with large-cell, anaplastic, or myc amplified medulloblastoma are also considered high risk. Standard treatment of this disease is craniospinal radiation with a boost on the primitive tumor bed, which results in a 5-year progression-free survival of about 50% to 60%.

In contrast, sPNET are rare tumors with a very poor prognosis of only 20% to 50% progression-free survival at 5 years. Despite differences in outcomes, patients with sPNET are treated according to the high-risk medulloblastoma protocols.

In this study, Dufour and colleagues wanted to improve 3-year progression-free survival in children with high-risk medulloblastoma or sPNET with treatment based on intensified chemotherapy before standard craniospinal radiotherapy and maintenance treatment with temozolomide. All patients in the study were aged 5 to 20 years and received no prior therapy.

After biopsy or initial surgery patients received postoperative induction chemotherapy two cycles of etoposide/carboplatin, followed by two courses of thiotepa (600mg/m2 per course) with autologous stem cell rescue. Risk-adapted conventional radiotherapy was delivered around day 45 after second transplantation. Maintenance treatment with six cycles of temozolomide was planned to start between 1 and 3 months after the end of radiotherapy. The median age of patients with medulloblastoma was 8; the median age of patients with sPNET was 13 years.

The median follow-up was 32 months. The 3-year progression-free survival rate was 79% for patients with medulloblastoma and 85% for patients with sPNET. The 3-year overall survival was 84% for patients with high-risk medulloblastoma and 92% for sPNET.

According to Dufour, patients experienced no major unexpected adverse events and no treatment-related deaths were reported.

Related Articles

  • Targeting Survivin May Open New Avenues for Immunotherapy
  • Common Genetic Driver Linked to Aggressive Meningiomas
  • Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies—PART 2: Existing Experience and Considerations for Future Trials
  • Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies—PART 1: Principles of Combined Treatment
  • Primary Central Nervous System Lymphoma—PART 2: Modern Therapeutic Management and Future Directions

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.